The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort

Un Jung Kang, Jennifer G. Goldman, Roy N. Alcalay, Tao Xie, Paul Tuite, Claire Henchcliffe, Penelope Hogarth, Amy W. Amara, Samuel Frank, Alice Rudolph, Cynthia Casaceli, Howard Andrews, Katrina Gwinn, Margaret Sutherland, Catherine Kopil, Lona Vincent, Mark Frasier

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Identifying PD-specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well-characterized, clinically typical, moderate to advanced PD cohorts is critically needed. Methods: BioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease) is a cross-sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites. Results: We present the study methodology and data on the cohort's clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls. Conclusion: Our cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum.

Original languageEnglish
Pages (from-to)924-932
Number of pages9
JournalMovement Disorders
Volume31
Issue number6
DOIs
StatePublished - 1 Jun 2016

Fingerprint

Parkinson Disease
Biomarkers
National Institute of Neurological Disorders and Stroke
Saliva
Multicenter Studies
Healthy Volunteers
Urine
RNA
DNA

Keywords

  • Biomarkers
  • Cerebrospinal fluid
  • DNA
  • Plasma
  • RNA
  • Saliva
  • Urine

Cite this

Kang, U. J., Goldman, J. G., Alcalay, R. N., Xie, T., Tuite, P., Henchcliffe, C., ... Frasier, M. (2016). The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement Disorders, 31(6), 924-932. https://doi.org/10.1002/mds.26613
Kang, Un Jung ; Goldman, Jennifer G. ; Alcalay, Roy N. ; Xie, Tao ; Tuite, Paul ; Henchcliffe, Claire ; Hogarth, Penelope ; Amara, Amy W. ; Frank, Samuel ; Rudolph, Alice ; Casaceli, Cynthia ; Andrews, Howard ; Gwinn, Katrina ; Sutherland, Margaret ; Kopil, Catherine ; Vincent, Lona ; Frasier, Mark. / The BioFIND study : Characteristics of a clinically typical Parkinson's disease biomarker cohort. In: Movement Disorders. 2016 ; Vol. 31, No. 6. pp. 924-932.
@article{1c3dfbd7aa814055affda8a64063c7f9,
title = "The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort",
abstract = "Background: Identifying PD-specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well-characterized, clinically typical, moderate to advanced PD cohorts is critically needed. Methods: BioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease) is a cross-sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites. Results: We present the study methodology and data on the cohort's clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls. Conclusion: Our cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum.",
keywords = "Biomarkers, Cerebrospinal fluid, DNA, Plasma, RNA, Saliva, Urine",
author = "Kang, {Un Jung} and Goldman, {Jennifer G.} and Alcalay, {Roy N.} and Tao Xie and Paul Tuite and Claire Henchcliffe and Penelope Hogarth and Amara, {Amy W.} and Samuel Frank and Alice Rudolph and Cynthia Casaceli and Howard Andrews and Katrina Gwinn and Margaret Sutherland and Catherine Kopil and Lona Vincent and Mark Frasier",
year = "2016",
month = "6",
day = "1",
doi = "10.1002/mds.26613",
language = "English",
volume = "31",
pages = "924--932",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

Kang, UJ, Goldman, JG, Alcalay, RN, Xie, T, Tuite, P, Henchcliffe, C, Hogarth, P, Amara, AW, Frank, S, Rudolph, A, Casaceli, C, Andrews, H, Gwinn, K, Sutherland, M, Kopil, C, Vincent, L & Frasier, M 2016, 'The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort', Movement Disorders, vol. 31, no. 6, pp. 924-932. https://doi.org/10.1002/mds.26613

The BioFIND study : Characteristics of a clinically typical Parkinson's disease biomarker cohort. / Kang, Un Jung; Goldman, Jennifer G.; Alcalay, Roy N.; Xie, Tao; Tuite, Paul; Henchcliffe, Claire; Hogarth, Penelope; Amara, Amy W.; Frank, Samuel; Rudolph, Alice; Casaceli, Cynthia; Andrews, Howard; Gwinn, Katrina; Sutherland, Margaret; Kopil, Catherine; Vincent, Lona; Frasier, Mark.

In: Movement Disorders, Vol. 31, No. 6, 01.06.2016, p. 924-932.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The BioFIND study

T2 - Characteristics of a clinically typical Parkinson's disease biomarker cohort

AU - Kang, Un Jung

AU - Goldman, Jennifer G.

AU - Alcalay, Roy N.

AU - Xie, Tao

AU - Tuite, Paul

AU - Henchcliffe, Claire

AU - Hogarth, Penelope

AU - Amara, Amy W.

AU - Frank, Samuel

AU - Rudolph, Alice

AU - Casaceli, Cynthia

AU - Andrews, Howard

AU - Gwinn, Katrina

AU - Sutherland, Margaret

AU - Kopil, Catherine

AU - Vincent, Lona

AU - Frasier, Mark

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: Identifying PD-specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well-characterized, clinically typical, moderate to advanced PD cohorts is critically needed. Methods: BioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease) is a cross-sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites. Results: We present the study methodology and data on the cohort's clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls. Conclusion: Our cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum.

AB - Background: Identifying PD-specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well-characterized, clinically typical, moderate to advanced PD cohorts is critically needed. Methods: BioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease) is a cross-sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites. Results: We present the study methodology and data on the cohort's clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls. Conclusion: Our cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum.

KW - Biomarkers

KW - Cerebrospinal fluid

KW - DNA

KW - Plasma

KW - RNA

KW - Saliva

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=84964661212&partnerID=8YFLogxK

U2 - 10.1002/mds.26613

DO - 10.1002/mds.26613

M3 - Article

C2 - 27113479

AN - SCOPUS:84964661212

VL - 31

SP - 924

EP - 932

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 6

ER -